IMUX

Immunic Inc

May 21 • 04:00PM ET

12.30

+0.75 6.49 %

Healthcare • Biotechnology • USA • Micro • NASD

Index	-	P/E	-	EPS (ttm)	-6.03	Insider Own	0.97%	Shs Outstand	13.62M	Perf Week	-2.81%
Market Cap	167.55M	Forward P/E	-	EPS next Y	-3.97	Insider Trans	0.00%	Shs Float	13.49M	Perf Month	36.67%
Enterprise Value	-18.66M	PEG	-	EPS next Q	-1.23	Inst Own	67.66%	Short Float	9.91%	Perf Quarter	30.85%
Income	-104.29M	P/S	-	EPS this Y	27.02%	Inst Trans	-	Short Ratio	4.53	Perf Half Y	61.84%
Sales	0.00M	P/B	1.11	EPS next Y	12.33%	ROA	-99.20%	Short Interest	1.34M	Perf YTD	130.47%
Book/sh	11.10	P/C	0.90	EPS next 5Y	16.71%	ROE	-142.91%	52W High	15.10 -18.54%	Perf Year	33.70%
Cash/sh	13.70	P/FCF	-	EPS past 3/5Y	45.16% 25.99%	ROIC	-68.89%	52W Low	5.06 142.99%	Perf 3Y	-33.87%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	- -	Gross Margin	-	Volatility	8.33% 9.88%	Perf 5Y	-90.84%
Dividend TTM	-	EV/Sales	-	EPS Y/Y TTM	38.59%	Oper. Margin	-	ATR (14)	1.04	Perf 10Y	-99.62%
Dividend Ex-Date	-	Quick Ratio	4.92	Sales Y/Y TTM	-	Profit Margin	-	RSI (14)	57.89	Recom	1.00
Dividend Gr. 3/5Y	- -	Current Ratio	4.92	EPS Q/Q	56.98%	SMA20	9.91%	Beta	1.24	Target Price	45.50
Payout	-	Debt/Eq	0.00	Sales Q/Q	-	SMA50	8.99%	Rel Volume	0.89	Prev Close	11.55
Employees	92	LT Debt/Eq	0.00	Earnings	May 13 BMO	SMA200	40.34%	Avg Volume	294.81K	Price	12.30
IPO	Apr 17, 2014	Option/Short	Yes / Yes	EPS/Sales Surpr.	-57.09% -	Trades		Volume	262,183	Change	6.49%

Date	Action	Analyst	Rating Change	Price Target Change
Apr-17-26	Initiated	Stifel	Buy	$2.50
Apr-15-26	Downgrade	D. Boral Capital	Buy → Hold
Mar-24-26	Initiated	Guggenheim	Buy	$7
Nov-07-25	Initiated	Roth Capital	Buy	$3
Sep-29-25	Initiated	Chardan Capital Markets	Buy	$13
Mar-25-25	Initiated	William Blair	Outperform
Nov-25-24	Initiated	H.C. Wainwright	Buy	$10
Sep-09-24	Resumed	Leerink Partners	Outperform	$5
Aug-27-24	Initiated	B. Riley Securities	Buy	$6
Oct-21-22	Downgrade	SVB Leerink	Outperform → Mkt Perform	$5
Sep-19-22	Resumed	H.C. Wainwright	Buy	$26
Apr-15-21	Initiated	Aegis Capital	Buy	$55
Mar-24-21	Initiated	JMP Securities	Mkt Outperform	$55
Oct-02-20	Initiated	SVB Leerink	Outperform	$45
Aug-26-20	Initiated	Piper Sandler	Overweight	$71
Aug-07-20	Resumed	ROTH Capital	Buy	$64
Jul-20-20	Initiated	BMO Capital Markets	Outperform	$40
Jun-05-20	Initiated	Wedbush	Outperform	$59
May-11-20	Initiated	H.C. Wainwright	Buy	$45
Mar-25-20	Initiated	ROTH Capital	Buy	$44

Show Previous Ratings

May-19-26 09:33AM	Immunic appoints Biogen, Cubist veteran Mike Bonney as board chair ahead of key MS trial readout (Proactive)
06:30AM	Immunic Appoints Seasoned Biopharmaceutical Executive Michael W. Bonney as Chair of the Board of Directors (PR Newswire)
May-13-26 09:04AM	Immunic advances Phase 3 MS program, eyes topline data by year-end (Proactive) +8.82%
07:48AM	Nasdaq continues to gain but Dow still red as Trump arrives in China (Proactive)
06:35AM	Immunic: Q1 Earnings Snapshot (Associated Press)
06:30AM	Loading…
06:30AM	Immunic, Inc. Reports First Quarter 2026 Financial Results and Provides Corporate Update (PR Newswire)
May-07-26 08:47AM	Immunic CEO on Q1 highlights, new appointments and upcoming milestones (Proactive) +6.62%
Apr-30-26 06:30AM	Immunic to Participate in Investor and Medical Conferences in May (PR Newswire)
Apr-28-26 08:40AM	Immunic appoints Michael Panzara as CMO ahead of pivotal MS drug readout (Proactive) +7.72%
06:30AM	Immunic Appoints Accomplished Biopharmaceutical Executive Michael A. Panzara, M.D., M.P.H., as Chief Medical Officer (PR Newswire)
Apr-23-26 08:52AM	Immunic to implement 1-for-10 reverse stock split (Proactive)
08:00AM	Immunic, Inc. Announces 1-for-10 Reverse Stock Split (PR Newswire)
Apr-09-26 06:30AM	Immunic to Participate in Scientific and Medical Conferences in April (PR Newswire) +8.40%
Apr-07-26 08:05AM	Immunic COO highlights the importance of science-led innovation to mark World Health Day (Proactive)
Apr-01-26 06:30AM	Immunic Regains Compliance with Nasdaq Minimum Bid Price Requirement (PR Newswire)
10:17AM	Loading…
Mar-31-26 10:17AM	Immunic appoints biopharmaceutical executive Jon Congleton to board (Proactive) +7.77%
06:30AM	Immunic Strengthens Its Board of Directors with the Appointment of Seasoned Biopharmaceutical Executive Jon Congleton (PR Newswire)
Mar-10-26 08:36AM	Immunic secures European patent for MS drug candidate vidofludimus calcium (Proactive)
06:30AM	Immunic Announces Grant of Key European Patent Protecting Relevant Dosing Regimens for Vidofludimus Calcium (PR Newswire)
Mar-03-26 07:08AM	Immunic to present at healthcare investor conferences in March (Proactive)
06:30AM	Immunic to Participate in Investor Conferences in March (PR Newswire)
Feb-28-26 03:00PM	Immunic secures $400M to support late-stage MS trials - ICYMI (Proactive)
Feb-26-26 09:02AM	Immunic sets stage for phase 3 MS data readout after $400M financing (Proactive)
07:08AM	Immunic: Q4 Earnings Snapshot (Associated Press Finance)
06:30AM	Immunic, Inc. Reports Year-End 2025 Financial Results and Provides Corporate Update (PR Newswire)
Feb-17-26 04:33PM	Immunic closes $200M private placement to fund late-stage MS trials (Proactive)
04:05PM	Immunic Announces Closing of Oversubscribed Private Placement Financing (PR Newswire)
Feb-16-26 06:09AM	Immunic secures $400m fund to support commercial-stage development (Pharmaceutical Business Review)
Feb-14-26 08:15AM	Immunic MS trial shows reduced brain lesions - ICYMI (Proactive)
Feb-13-26 01:55PM	Why Is Immunic Stock Soaring Friday? (Benzinga)
11:25AM	Loading…
11:25AM	Immunic Stock Jumps After Pricing $400 Million Private Placement (Benzinga)
11:20AM	Immunic shares gain on $400M raise to fund late-stage MS trials, commercial push (Proactive)
09:03AM	Immunic to raise up to $400M to fund late-stage MS trials, commercial push (Proactive)
06:30AM	Immunic Announces Oversubscribed Private Placement of up to USD 400 Million to Accelerate Transformation into Commercial-Stage Company (PR Newswire)
Feb-10-26 08:11AM	Immunic showcases Phase 2 data on vidofludimus calcium at ACTRIMS Forum (Proactive) +11.30%
Feb-04-26 08:45AM	Immunic to present additional Phase 2 data on vidofludimus calcium in progressive MS (Proactive) -5.43%
06:30AM	Immunic to Present Additional Phase 2 CALLIPER Trial Data for Vidofludimus Calcium at the ACTRIMS Forum 2026, Reinforcing Its Potential in Progressive Multiple Sclerosis (PR Newswire)
Jan-12-26 04:23AM	Immunic (IMUX) Reviews 2025 Performance and Highlights Upcoming Milestones, Shares Up 24.10% (Insider Monkey)
Jan-07-26 06:30AM	Immunic Highlights 2025 Accomplishments and Upcoming Milestones (PR Newswire) +10.67%
Nov-26-25 06:30AM	Immunic to Participate in the 8th Annual Evercore ISI Healthcare Conference in December (PR Newswire)
Nov-13-25 06:39AM	Immunic: Q3 Earnings Snapshot (Associated Press Finance) -6.24%
06:30AM	Immunic, Inc. Reports Third Quarter 2025 Financial Results and Provides Corporate Update (PR Newswire)
Nov-07-25 09:33AM	Datadog, Trade Desk upgraded: Wall Street's top analyst calls (The Fly)
Oct-29-25 06:30AM	Immunic to Participate in Industry and Investor Conferences in November (PR Newswire) -5.01%
Oct-01-25 06:30AM	Immunic to Participate in Scientific and Investor Conferences in October (PR Newswire) +8.89%
Sep-25-25 06:30AM	Immunic Presented Key Vidofludimus Calcium Data at the 41st Congress of ECTRIMS, Highlighting Its Potential in Multiple Sclerosis (PR Newswire)
Sep-09-25 06:30AM	Immunic Receives Notice of Allowance for United States Patent Protecting Vidofludimus Calcium's Dose Strengths in Progressive Multiple Sclerosis (PR Newswire)
Sep-04-25 06:30AM	Immunic to Participate in Investor and Scientific Conferences in September (PR Newswire)
Aug-07-25 06:37AM	Immunic: Q2 Earnings Snapshot (Associated Press Finance) -7.87%
06:30AM	Immunic, Inc. Reports Second Quarter 2025 Financial Results and Provides Corporate Update (PR Newswire)
Jul-25-25 12:22PM	Immunic Reports Positive Long-Term Safety, Tolerability Data for Vidofludimus Calcium in MS Trial (Insider Monkey)
Jun-24-25 06:30AM	Immunic Reports New, Positive Long-Term Open-Label Extension Data From Phase 2 EMPhASIS Trial of Vidofludimus Calcium in Relapsing-Remitting Multiple Sclerosis (PR Newswire)
Jun-05-25 06:30AM	Immunic Announces Completion of Enrollment for Both Phase 3 ENSURE Trials in Relapsing MS and Presents Additional Data Underlining Positive Outcome of Phase 2 CALLIPER Trial in Progressive MS (PR Newswire)
Jun-03-25 04:01PM	Immunic, Inc. Announces Closing of Oversubscribed $65 Million Underwritten Public Offering (PR Newswire) +6.11%
Jun-02-25 06:30AM	Immunic to Participate in Investor, Scientific and Industry Conferences in June (PR Newswire) +6.08%
May-29-25 07:05AM	Immunic, Inc. Announces Pricing of Oversubscribed $65 Million Underwritten Public Offering (PR Newswire) -25.28%
May-28-25 04:02PM	Immunic, Inc. Announces Proposed Public Offering (PR Newswire)
May-15-25 06:24PM	Immunic: Q1 Earnings Snapshot (Associated Press Finance)
May-02-25 06:30AM	Immunic to Participate in Scientific and Industry Conferences in May (PR Newswire)
May-01-25 01:56PM	Immunic presses ahead with MS drug despite Phase II endpoint miss (Clinical Trials Arena) +18.17%
Apr-30-25 07:30AM	Immunic Announces Vidofludimus Calcium Reduced Risk of Disability Worsening by 30% in Primary Progressive Multiple Sclerosis Patients from Phase 2 CALLIPER Trial (PR Newswire) -22.65%
Apr-28-25 02:09AM	Immunic: A Strong Buy With Imminent Data Readout That Should Send Shares Higher (Seeking Alpha)
Apr-10-25 01:00PM	Immunic, Inc. Announces Closing of $5.1 Million Registered Direct Offering, Led by Aberdeen Investments (PR Newswire)
Apr-09-25 08:10AM	Immunic, Inc. Announces Pricing of $5.1 Million Registered Direct Offering, Led by Aberdeen Investments (PR Newswire)
Apr-01-25 06:30AM	Immunic, Inc. to Participate in Scientific and Industry Conferences in April (PR Newswire)
Mar-03-25 06:30AM	Immunic to Participate in Scientific and Investor Conferences in March (PR Newswire)
Feb-26-25 06:30AM	Immunic Presents Key Vidofludimus Calcium Data at the ACTRIMS Forum 2025, Highlighting Its Potential in Multiple Sclerosis (PR Newswire)
Feb-20-25 07:30AM	Immunic's Oral IMU-856 Demonstrated Dose-Dependent Increase of GLP-1 in Celiac Disease Patients and Corresponding Effects in Preclinical Testing (PR Newswire) +12.38%
Feb-04-25 06:30AM	Immunic to Participate in Investor and Scientific Conferences in February (PR Newswire)
Jan-07-25 06:30AM	Immunic Highlights 2024 Accomplishments and Upcoming Milestones (PR Newswire)
Dec-03-24 03:45PM	Winter 2024 Investor Summit Virtual: Q4 Presentations Now Available for On-Demand Viewing (ACCESS Newswire) -9.29%
Nov-26-24 06:30AM	Immunic, Inc. to Participate in Investor Conference in December (PR Newswire)
Nov-14-24 06:35AM	Immunic announces publication of IMU-856 data (TipRanks) -6.84%
Nov-13-24 06:30AM	Immunic Announces Publication of Data From Phase 1/1b Clinical Trial of IMU-856 in the Peer Reviewed Journal, The Lancet Gastroenterology & Hepatology (PR Newswire)
Nov-09-24 08:00AM	Immunic Inc (IMUX) Q3 2024 Earnings Call Highlights: Strategic Progress Amid Financial Challenges (GuruFocus.com)
Nov-07-24 06:41AM	Immunic: Q3 Earnings Snapshot (Associated Press Finance)
06:30AM	Immunic, Inc. Reports Third Quarter 2024 Financial Results and Provides Corporate Update (PR Newswire)
Oct-31-24 06:30AM	Immunic, Inc. to Announce Financial Results for the Third Quarter Ended September 30, 2024, and Provide Corporate Update (PR Newswire)
Oct-29-24 06:30AM	Immunic to Participate in Industry, Scientific and Investor Conferences in November (PR Newswire)
Oct-22-24 06:30AM	Immunic Announces Positive Outcome of Interim Analysis of Phase 3 ENSURE Program of Vidofludimus Calcium in Relapsing Multiple Sclerosis (PR Newswire) -9.68%
Oct-09-24 05:31PM	Immunic Inc (IMUX) Q2 2024 Earnings Call Highlights: Promising Clinical Data and Financial ... (GuruFocus.com) -6.67%
Sep-18-24 06:30AM	Immunic Presents Key Vidofludimus Calcium Data at the 40th Congress of ECTRIMS, Highlighting Its Therapeutic Potential in Multiple Sclerosis (PR Newswire) +11.18%
Sep-04-24 06:30AM	Immunic Announces First Patient Enrolled in Investigator-Sponsored Phase 2 Clinical Trial of Vidofludimus Calcium in Patients with Post COVID Syndrome (PR Newswire)
Aug-28-24 06:30AM	Immunic to Host Multiple Sclerosis R&D Day and Participate in Scientific and Investor Conferences in September (PR Newswire)
Aug-08-24 06:34AM	Immunic: Q2 Earnings Snapshot (Associated Press Finance) +14.53%
06:30AM	Immunic, Inc. Reports Second Quarter 2024 Financial Results and Provides Corporate Update (PR Newswire)
Aug-01-24 06:30AM	Immunic, Inc. to Announce Financial Results for the Second Quarter Ended June 30, 2024, and Provide Corporate Update (PR Newswire)
Jul-24-24 06:30AM	Immunic, Inc. Strengthens Its Board of Directors with the Appointment of Experienced Pharmaceutical Executive Simona Skerjanec (PR Newswire) -5.48%
Jul-09-24 06:30AM	Immunic Appoints Jason Tardio as Chief Operating Officer and President (PR Newswire) +7.76%
May-30-24 07:03AM	Immunic Inc. CEO Daniel Vitt Highlights Advances in MS Treatment on World MS Day (News Direct)
May-28-24 06:30AM	Immunic to Participate in Industry and Scientific Conferences in June (PR Newswire)
May-23-24 06:00AM	Peek Behind the Curtain: 7 Penny Stocks With Heavy Insider Buying (InvestorPlace)
May-20-24 10:00AM	Immunic CMO discusses role of clinical trials in biotech development for Clinical Trials Day (News Direct)
May-17-24 02:35PM	Immunic chief medical officer discusses promising treatments to mark World IBD Day (News Direct)
May-16-24 05:54PM	Immunic highlights IMU-856 gastrointestinal candidate to mark International Celiac Day (News Direct)
May-09-24 10:23AM	Immunic, Inc. (NASDAQ:IMUX) Q1 2024 Earnings Call Transcript (Insider Monkey)
06:58AM	Immunic CEO Dr Daniel Vitt discusses key Q1 advances and upcoming milestones (News Direct)
May-08-24 06:36AM	Immunic: Q1 Earnings Snapshot (Associated Press Finance) -7.97%
06:30AM	Immunic, Inc. Reports First Quarter 2024 Financial Results and Provides Corporate Update (PR Newswire)
May-06-24 06:30AM	Immunic to Participate in Investor and Scientific Conferences in May (PR Newswire)

Immunic, Inc. is a clinical-stage biopharmaceutical company, which develops a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases. It focuses on ulcerative colitis, Crohn's disease, relapsing-remitting multiple sclerosis, and psoriasis. The firm's products include IMU-838, IMU-935, and IMU-856. The company was founded in May 2003 and is headquartered in New York, NY.

CEO & DirectorDr. Daniel Vitt Ph.D.

COO & PresidentMr. Jason Tardio M.B.A.

Chief Financial OfficerMr. Glenn Whaley CPA

Chief Scientific OfficerDr. Hella Kohlhof

Head of Investor Relations & CommunicationsMs. Jessica Breu

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Nash Duane	Executive Chairman	Jun 13 '25	Buy	0.83	20,000	16,694	36,032	Jun 16 05:00 PM
Tardio Jason	President and COO	Jun 05 '25	Buy	0.79	12,512	9,884	12,512	Jun 09 04:07 PM
Vitt Daniel	CEO and Director	Jun 04 '25	Buy	0.77	15,000	11,550	29,000	Jun 06 05:00 PM
Neermann Joerg	Director	Jun 04 '25	Buy	0.77	70,000	53,900	170,000	Jun 05 04:07 PM
Neermann Joerg	Director	Jun 05 '25	Buy	0.76	30,000	22,800	200,000	Jun 05 04:07 PM
Whaley Glenn	Chief Financial Officer	Jun 03 '25	Buy	0.71	45,000	32,076	95,510	Jun 04 04:22 PM
Rudick Richard Alan	Director	Jun 03 '25	Buy	0.70	143,075	100,024	230,375	Jun 04 04:06 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

IMUX

Immunic Inc

Upgrade your Finviz experience